Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of DP-R202 vs Anplag in Peripheral Arterial Disease
NCT02393612Phase 3Completed
- Sponsor
- Alvogen
- Start
- Oct 2012
- Primary completion
- Apr 2014
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of sarpogrelate in Peripheral Arterial Disease (PAD), sponsored by Alvogen. Started Oct 2012; status: completed.
02
Drugs
sarpogrelate
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT02393612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02393612.